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Summary 
Increasing evidence suggests that the metabolism of arachidonic acid (AA) may be different in 
inflammatory cells isolated from blood or migrating into tissues.  To explore the possibility that 
changes in AA metabolism between blood and tissue inflammatory cells could be due in part to 
a different content or distribution of AA in glycerollpid classes, we studied these parameters in 
six human  inflammatory cells  isolated from blood  (eosinophils,  monocytes,  neutrophils,  and 
platelets) or from the lung tissue (mast cells and macrophages). Lung cells generally had a higher 
total cellular content of AA than that found in the blood cells.  In addition, both mast cells and 
macrophages had a large endogenous pool of AA associated with triglycerides (TG), containing 
45 and 22% of their total cellular AA, respectively. To address the hypothesis that cells migrat- 
ing into the lung had a higher cellular level of  AA and a larger AA pool in TG, we studied neu- 
trophils isolated from the bronchoalveolar Iavage (BAL) of patients with adult respiratory dis- 
tress syndrome. BAL neutrophils had a fourfold increase in cellular AA as compared with blood 
neutrophils and contained 25% of their AA in TG versus 3% in blood neutrophils. BAL neu- 
trophils also had a higher number of cytoplasmic lipid bodies  (8  +  3/cell)  relative to blood 
neutrophils (2  +  1/cell). High concentrations of free AA were also found in the cell-free BAL 
fluid of adult respiratory distress  syndrome patients. To explore whether changes in BAL neu- 
trophils may be due to the exposure of the cells to high concentrations of exogenous AA found 
in BAL, we incubated blood neutrophils in culture with AA (10-100  p,M) for 24 h. Neutro- 
phils supplemented with AA had a  10-fold increase in the amount of AA associated with TG 
and a sixfold increase in the number of lipid bodies. In addition, supplementation with AA in- 
duced a dose-dependent formation of hypodense cells. Taken together, these data indicate that 
human inflammatory cells  undergo  a fundamental  and consistent remodeling of AA pools as 
they mature or enter the lung from the blood. These biochemical and morphological changes 
can be mimicked in vitro by exposing the cells to high levels of AA. This mechanism may be 
responsible for the changes in AA mobilization and eicosanoid metabolism observed in tissue 
inflammatory cells. 
E 
icosanoids  are  ox-ygenase-derived metabolites  of ara- 
chidonic acid (AA) 1 involved in the pathogenesis of in- 
flammatory and  allergic  reactions  (1-3).  The amount and 
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ratory distress syndrome; BAL, bronchoalveolar  lavage; 2Hs-AA, octadeu- 
terio AA; 2H3-SA. trideuterio stearic acid; LA, linoleic acid; NICI-GC/ 
MS,  negative ion  chemical ionization-gas chromatography/mass spec- 
trometry; NL, neutral lipids; OA, oleic acid; PI, phosphatidylinositol; PC, 
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the profile of eicosanoids produced by inflammatory cells is 
dictated by a variety of biochemical factors, including  the 
activity of biosynthetic  enzymes (phospholipases A2, pros- 
taglandin synthases, and lipoxygenases) and the availability 
of AA  in  cellular glycerolipid pools  (4-7).  A  number  of 
studies have shown that AA metabolism can be both quan- 
titatively  and  qualitatively  different  in  inflammatory cells 
obtained  from  blood  and  those  resident  in  or  migrating 
into tissues  (8, 9).  For example, blood monocytes produce 
different  quantities  and  a  distinct  profile  of  eicosanoids 
from those  generated  by tissue  macrophages  (10,  11).  In 
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AA differently  than  those  isolated  from blood,  and  these 
differences  are  associated  with  phenotypic  and  density 
changes of the  cells  (12-14).  Part of these differences may 
be related to microenvironmental factors in the lung, such 
as  cytokines  and  growth  factors,  to which  tissue  cells  are 
exposed (15, 16). For example, several cytokines have been 
shown  to substantially  influence  enzymes involved in AA 
metabolism (17, 18). However, there is increasing evidence 
that remodeling of AA into certain glycerolipid pools or in 
distinct subcellular locations may be an important factor in 
regulating AA metabolism in these inflammatory cells.  De- 
fining these factors may help elucidate the pathophysiolog- 
ical role of inflammatory cells  that move into or reside  in 
the lung. 
Recent  studies  have  emphasized  the  importance  of the 
cellular  compartmentalization  of AA  metabolism  and,  in 
particular,  of the  subcellular  distribution  of glycerolipid 
pools  of AA as  well  as  of the  enzymes  that  act  on  these 
pools. For example,  both high molecular weight phospho- 
lipase  A 2 and  5-1ipoxygenase appear to  translocate  from a 
cytosolic to  a  nuclear location during  cell  activation  (19- 
21).  It  is  thought  that  this  translocation  is  necessary  to 
move  these  enzymes  to  their  AA-containing  substrates. 
5-1ipoxygenase-activating protein has also been localized to 
the  nuclear  envelope  (21).  Studies  by  S.  T.  Reddy  and 
H. 1K.  Herschman suggest that  one  isotype  of PG  H  syn- 
thase (PG/H synthase II) uses exogenous AA while another 
isotype  (PG/H  synthase  I)  uses  glycerolipid  pools  of AA 
within  the  cell  (7).  Our studies  in mast  cells  indicate  that 
there are distinct glycerolipid pools at separate cellular loca- 
tions that supply AA that forms leukotrienes  or AA that is 
released unmetabolized from the cell (22, 23). 
Even though the cellular compartmentalization of differ- 
ent glycerolipid pools of AA appears to be important in AA 
mobilization  and  eicosanoid  generation,  little  is  known 
about the  location and function  of individual  glycerolipid 
pools.  In  general,  the  major  glycerolipid  pools  of  AA 
within inflammatory cells that supply AA have been assumed 
to be  located within  membrane  phospholipids.  However, 
even  this  basic  assumption  has been  challenged  by recent 
studies that indicate a large pool of AA associated with tri- 
glycerides (TG) in human macrophages (24). 
The goal of the current study was to begin to test the hy- 
pothesis that human inflammatory cells,  reaching their final 
maturation in the lung or migrating in the lung during an 
inflammatory reaction,  metabolize  AA differently because 
they  remodel  their  AA into  unique  glycerolipid  pools  at 
distinct subcellular locations. This study indicates that most 
human blood inflammatory cells  (neutrophils,  monocytes, 
and platelets)  contain  a  small  pool of AA in TG,  but  this 
pool is substantially larger in lung resident  cells  (mast cells 
and macrophages).  In addition,  the  quantity of AA associ- 
ated with the TG pool is directly correlated with the total 
content of AA in each cell. Finally, our data show that the 
increase  in  AA within  the  TG  pool  is  associated  both  in 
vitro and in vivo with an increased number of cytoplasmic 
lipid bodies and with the formation ofhypodense cells. 
Materials  and Methods 
Materials.  Radiolabeled [3,6,8,9,11,12,14,15-3H]-AA  (80 Ci/ 
mmole)  was  purchased  from  New  England  Nuclear  Products 
(Boston,  MA).  AA,  octadeutero  AA  (2Hs-AA),  and  trideutero 
stearic  acid (2H3-SA) were purchased from BIOMOL Research 
Laboratories  Inc.  (Plymouth Meeting,  PA).  cx-Naphthyl  acetate 
esterase kit,  Ficoll, Percoll,  and insulin/transferrin/sodium  selen- 
ite  supplement  were  purchased from Sigma  Chemical  Co.  (St. 
Louis,  MO).  Essentially  fatty  acid-free  human  serum  albumin, 
pyridine, and pentafluorobenzoyl chloride were purchased from 
Aldrich Chemical Co. (Milwaukee,  WI). Nile red was purchased 
from Polysciences  Inc. (Wanington, PA). ILPMI 1640 and FCS 
were obtained from GIBCO BILL (Gaithersburg,  MD). All sol- 
vents were HPLC grade  and were purchased from Fisher Scien- 
tific Co. (Norcross,  GA). 
Cell  Preparation.  Neutrophils,  eosinophils,  monocytes,  and 
platelets  were isolated  from the peripheral  blood of healthy do- 
nors after overnight fasting.  Neutrophils were prepared by dex- 
tran sedimentation followed by centrifugation over Ficoll (density 
1.077), as previously described  (25). Eosinophils  were purified  by 
a negative selection  technique reported by Hansel et al. using im- 
munomagnetic beads  (Perseptive  Diagnostics,  Cambridge,  MA) 
coated with a mAb anti-CD16 (3G8 monoclonal, a generous gift 
from Dr. Jay Unkeless,  Mount Sinai  School of Medicine,  NY) 
(26). Monocytes were isolated from the mononuclear cell fraction 
floating  over the  Ficoll  gradient  (11). Mononuclear  cells were 
suspended  (106/ml) in ILPMI 1640 containing 2 mM glutamine, 
100 Ixg/ml penicillin,  and 100 btg/ml streptomycin and were in- 
cubated for 4 h in plastic dishes at 37~  in 5% CO2. After the in- 
cubation, nonadherent cells were removed by washing the plates 
twice  with  tLPMI  1640.  Adherent  cells  were  identified  as 
>90% monocytes by cx-naphthyl acetate  esterase staining.  Con- 
taminating platelets  adhering to the surface of monocytes at the 
end of the incubation were <2% as visualized by phase-contrast 
microscopy. Platelets  were isolated  from platelet-rich  plasma,  as 
previously described  (27). Lung macrophages and mast cells were 
obtained from the lung parenchyma of patients  undergoing tho- 
racic surgery according to previously described  techniques  (28). 
Briefly,  macrophages were isolated  by flotation over discontinu- 
ous  Percoll  gradients  followed by  adherence  to  plastic  dishes. 
Macrophage  purity  was  determined  by ci-naphthyl  acetate  es- 
Table 1.  Total Arachidonate Content  of Human Inflammatory 
Cells 
Cells  n  Purity range  AA 
%  nmoles / I06 cells 
Blood cells 
Monocyte  3  90-95  5.4 +  1.1 
Platelet  5  98-100  0.01  +  0.004 
Neutrophil  4  97-99  1.3 +  0.1 
Eosinophil  4  91-96  3.7 ___ 0.3 
Tissue lung cells 
Mast cell  4  85-92  8.6  +- 2.4 
Macrophage  5  93-97  5.3 -  0.5 
Inflammatory cells were  isolated as described. Lipids were  then  ex- 
tracted by the method ofE. G. Bligh and W. J. Dyer (30), and the total 
AA content in all lipids was measured by NICI-GC/MS. 
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of the lung tissue followed by countercurrent centrifugation elu- 
triation and flotation over Percoll density gradients. Mast cell pu- 
rity was  determined  by  Alcian blue  staining.  The  number  of 
preparations and the range of purity of cells used in this study are 
reported in Table 1. 
Isolation of Neutrophils from the Bronchoalveotar Lavage (BAL) of 
Patients with Adult  Respiratory Distress Syndrome (ARDS).  BAL 
fluid was obtained from three patients with ARDS. In all three 
patients, ARDS developed as a sequela of pneumonia. BAL was 
performed by  injecting 3  60-ml  aliquots  of prewarmed  saline. 
Recovery of the fluid ranged from 50 to 60%. The average num- 
ber of neutrophils in the BAL fluids was 6.5  ￿  106 cells/ml with 
a purity ranging from 48 to 67%.  After a brief (15-s)  hypotonic 
lysis  to  eliminate  contaminating  erythrocytes,  cells  were  sus- 
pended (106 cells/rnl) in R.PMI 1640 without FCS and incubated 
for 60 rain in plastic dishes.  This procedure allowed the adher- 
ence of macrophages, which were the major contaminating cells 
of our preparations. At the end of the incubations, nonadherent 
cells were harvested and counted. The purity of neutrophils after 
this procedure was 82  +  2%. 
Culture of Neutrophils Supplemented with AA.  Immediately af- 
ter isolation, neutrophils were suspended (2  ￿  106 cells/m])  in 
R.PMI 1640 containing 1% FCS, 5 gtg/ml insulin, 5 tzg/ml trans- 
ferrin, and 5 ng/ml sodium selenite. The cells were supplemented 
with  10,  50,  or 100  IzM AA bound to HSA (1  mg/ml). These 
relatively high concentrations were chosen because much of the 
AA provided to the cells is rapidly bound by serum components 
in the culture media. After a 24-h incubation period, cells were 
harvested and counted,  and viability was determined by trypan 
blue staining. The percentages of cell recovery after culture were 
as follows (mean +  SE, n =  4): 82 +  5, 79 +  3, 71  +  4, and 69 _+ 
4 for unsupplemented cells and cells supplemented with 10,  50, 
and  100  btM  AA,  respectively. The  percentage  of viable cells 
among  those  recovered was  similar in  each  group  and  ranged 
from 91 to 97%. 
Lipid Bodies Count and Evaluation of Hypodense Cells.  Cytoplasmic 
lipid bodies in neutrophils from normal peripheral blood, neutro- 
phils  exposed  to  exogenous  AA,  and  BAL  neutrophils  from 
ARDS  patients were  stained with  Nile  red,  as  previously de- 
scribed (29). Briefly, cells were incubated for 5 rain at 22~  in the 
dark with Nile red (1 I.tg/ml). The lipid bodies were then visual- 
ized under a fluorescent microscope (IM 35; Carl Zeiss Inc., New 
York)  using 488  nm  excitation with  >510  nm  emission.  The 
number of lipid bodies was  counted in at least 25  cells of each 
preparation. 
The  number  of hypodense cells was  determined by using a 
cut-off density of 1.077.  Freshly isolated neutrophils and neutro- 
phils supplemented with AA were layered over 3  ml of Ficoll- 
Paque and centrifuged at 1,200 g for 20 rain at 4~  The percent- 
age of hypodense cells was calculated by counting the number of 
cells remaining on the top of the gradient. 
Lipid Extraction and  Chromatography.  Lipids were  extracted 
from the cell pellets by a modified procedure of E. G. Bligh and 
W. J.  Dyer in which sufficient formic acid was added to lower 
the pH of the aqueous phase to 3.0 (30). Cells adherent to plastic 
dishes (monocytes and macrophages) were directly scraped offthe 
plate with a rubber policeman in a mixture of methanol/water (2:1, 
vol/vol). After the  extraction,  solvents were  removed under  a 
stream of nitrogen, and the lipids were resuspended in  chloro- 
form/methanol  (1:1,  vol/vol).  Lipid classes were  separated by 
normal-phase  HPLC  on  silica columns  using  a  mobile  phase 
composed of hexane/2-propanol/ethanol/phosphate buffer (490: 
367:100:30,  vol/vol). After  10  rain  of the  run,  the volume  of 
phosphate buffer was increased from 30 to 50 over 5 min.  The 
flow was maintained at 1 ml/min, and 1-ml fractions were col- 
lected throughout  the  run.  Absorbance was  monitored at  206 
nm. Authentic glycerolipid standards were run before each bio- 
logical sample to  determine the  retention times of glycerolipid 
classes. 
Neutral lipid classes  (mono-,  di-,  and  triglycerides and  free 
AA) were isolated by TLC over layers of silica gel G developed in 
hexane/diethyl ether/formic acid  (90:60:6,  vol/vol). Each  class 
was located on the silica gel by parallel runs of standards and was 
eluted with  chloroform/methanol  (1:1,  vol/vol).  The  recovery 
was similar for all neutral lipid classes and was always >80%. 
Negative Ion Chemical Ionization-Gas Chromatography~Mass Spec- 
trometry (NICI-GC/MS) Of  AA and Other Fatty Adds.  The mole 
quantities of AA, oleic acid (OA), and linoleic acid (LA) in each 
lipid class isolated by normal-phase HPLC or by TLC were de- 
termined by NICI-GC/MS. 2Hs-AA and 2H3-SA  (100 ng each) 
were added as internal standards to each lipid fraction. Fatty acids 
were liberated from glycerolipids by base hydrolysis by using 2 M 
KOH in 75% ethanol (30 rain, 60~  The reaction was stopped 
by the addition of an equal amount of water, and the reaction 
mixture was adjusted to pH 3.0 with 6-N hydrochloric acid. Free 
fatty acids were extracted with diethyl ether. Recovery of internal 
standards was  >80%.  Fatty acids were  then  converted to  pen- 
tafluorobenzylesters, and the mole quantities of fatty acids were 
determined by combined NICI-GC/MS by using a mass spectrom- 
eter (model 5989;  Hewlett-Packard Co., Palo Alto, CA), as pre- 
viously described  (24).  Carboxylate anions  (m/z)  at  279,  281, 
286,  303,  and 311  for LA, OA, 2H3-SA,  AA, and 2Hs-AA, re- 
spectively, were measured in the selected ion monitoring mode. 
The typical area beneath the peak was 2.0  ￿  105 to 5.0  ￿  105 for 
2Hs-AA and 9.0 ￿  105 to 1.2 ￿  106 for 2H3-SA. 
Results 
AA  Content  and  Distribution  in  Phospholipid and  Neutral 
Lipid Pools of Blood and Lung Tissue Inflammatory Cells. Ini- 
tial experiments were performed to determine the total AA 
content and the distribution of endogenous AA in the glyc- 
erolipid classes of human inflammatory cells isolated either 
from blood (neutrophils, eosinophils, platelets, and mono- 
cytes) or from the lung tissue (mast cells and macrophages). 
Table  1 shows the number of preparations, the cell purity, 
and  the  total AA content  in  the  six cells examined.  The 
cellular content of AA within the cells was highly variable, 
with  amounts  ranging  from  8.6  -+  2.4  nmoles/106  mast 
cells to 0.01  +  0.004 nmoles/106 platelets. The distribution 
of AA in  the  major glycerolipid classes  of the  six cells is 
shown in Fig. 1. In all cells, phosphatidylethanolamine (PE) 
and phosphatidylcholine (PC) were the major AA-contain- 
ing phospholipid pools, and PE was the predominant pool 
in neutrophils, monocytes, and platelets. As previously re- 
ported,  the  macrophage  was  the  only  cell  in  which  AA 
could be measured in bis-monoacyl-glyceryl phosphate, an 
unusual  phospholipid  derived  from  phosphatidylglycerol 
(24).  In all cells,  other classes of phospholipids, including 
lysophospholipids,  sphingomyelin,  cardiolipin,  and  phos- 
phatidic acid,  contained  a  negligible amount  of AA  (data 
not shown).  In contrast with  the relative homogeneity of 
AA distribution within the phospholipid classes among the 
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Figure 1.  Distribution of AA in the glycer- 
olipid  classes of  blood  inflammatory  cells 
(monocytes, platelets, neutrophils, and  eosi- 
nophils) and of lung tissue inflammatory cells 
(mast cells and macrophages). Cells  were iso- 
lated and purified  as  described in  Materials 
and Methods. Lipids were extracted and sepa- 
rated by normal-phase HPLC.  The quantiw 
of AA in each glycerolipid class  was measured 
by NICI-GC/MS. The  results are expressed 
as the percentage of total cellular AA and are 
the mean -+ SE of the number of preparations 
indicated  in  Table  1.  BMP, bis-monoacyl- 
glyceryl phosphate. 
different  cell  types,  there  was  a  wide  variation  in  the 
amount  of AA associated with neutral lipids. In particular, 
45  -+ 9 and 23  +  6% of the total cellular AA was esterified 
in the neutral lipids of mast cells and macrophages, respec- 
tively, whereas only 3.0  +  0.5%  of cellular AA was found 
in this class in neutrophils. 
The neutral lipid fraction from mammalian ceils is gener- 
ally composed of various molecules including mono-,  di-, 
and triglycerides and unesterified fatty acids. To determine 
which of these neutral lipid classes contained AA, we iso- 
lated the  neutral  lipids of mast  cells and  macrophages  by 
TLC  and  measured  the  mole  quantities  of AA into  each 
class by GC/MS  (Table  2).  Direct mass measurements  of 
neutral  lipids in  these  two  cell  types  indicated  that  most 
(~80%)  of AA was esterified in TG. 
Two  important observations were made from these ini- 
tial experiments. First, cells that have a high content of cel- 
lular AA distribute a larger portion of their AA into a TG 
pool.  Second,  inflammatory cells found  in  the  lung  (mast 
cells and macrophages) contain large quantities of AA and a 
large pool of AA in TG. 
AA Content and Distribution in Neutrophils Isolated  from  the 
BAL  Fluid  of  Patients with  ARDS.  The  data  reported 
above indicated that inflammatory cells resident in the lung 
contain both large amounts of total cellular AA and a high 
amount  of AA  esterified into  TG  when  compared  with 
most cells circulating in the blood. We therefore hypothe- 
sized  that  cell  migration  into  the  lung  is  associated with 
changes  in AA content  and  distribution,  To  test  this  hy- 
pothesis directly, we studied neutrophils, a cell in the blood 
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Cells and Macrophages 
Neutral lipids 
Percentage of AA in neutral lipids 
Lung mast cell  Lung macrophage 
Monoglycerides  2.1  3.8 
Diglycerides  2.5  6.3 
Triglycerides  83.3  81.3 
Free AA  12.1  8.6 
Lung mast cells and macrophages were purified from human lung tissue 
as described in Materials and Methods.  Lipids were  extracted and the 
neutral lipid classes  were isolated by TLC.  The amount of AA in each 
neutral lipid class was determined by NICI-GC/MS. The data are ex- 
pressed as the percentage of the total neutral lipid-associated AA and are 
the mean of two preparations of mast cells and two preparations ofmac- 
rophages. 
that has a  low amount  of cellular AA and a  small pool of 
AA in TG, in an in vivo model of migration into the lung. 
In this set  of experiments, neutrophils were  isolated from 
the BAL fluid of three patients with ARDS. This syndrome 
is  characterized by severe  respiratory distress,  hypoxemia, 
and  lung  edema.  Almost invariably, patients  with  ARDS 
have a marked neutrophil infiltration of the airways (31). 
Total AA content and distribution of AA among glycer- 
olipid classes was  determined in neutrophils isolated from 
BAL  of ARDS  patients.  The  average  content  of cellular 
AA in these  cells was 4.3  +  1.2  nmoles/106  cells, a value 
almost fourfold higher than that found in peripheral blood 
neutrophils  from  healthy  donors  (1~3  +  0.4  nmoles/106 
cells). Fig.  2  shows  the  distribution of AA in glycerolipid 
classes of BAL neutrophils from ARDS patients.  In all pa- 
tients,  the  amount  of AA  in  the  neutral  lipid  pool  was 
~30-fold larger than it was in peripheral blood neutrophils 
from healthy donors  (Fig.  1).  In one of the three patients, 
the  TG  pool  was  the  largest  AA-containing glycerolipid 
class in  the BAL neutrophils.  Further analysis of the  fatty 
acids in the TG pool indicated that other fatty acids, in ad- 
dition to AA, were increased in this pool in the BAL neu- 
trophils. Table 3 shows that the mole quantities ofLA, OA, 
and  AA in  TG  of BAL neutrophils  increased  7-,  9-,  and 
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Figure 2.  Distribution of AA in the glycerolipid classes of neutrophils 
isolated from BAL of three patients with ARDS. Cells were isolated and 
purified as described in Materials and Methods. Lipids were extracted and 
separated by normal-phase HPLC. The quantity of AA in each class was 
measured by NICI-GC/MS. The results are expressed as the percentage 
of total cellular AA and are the mean +  SE of three experiments. 
13-fold, respectively, when compared with peripheral neu- 
trophils from normal donors. Moreover, the ratios of LA to 
AA and  OA  to  AA were  significantly reduced  in  TG  of 
BAL neutrophils, suggesting some selectivity for AA incor- 
poration into TG. 
It has been recognized for several years that the density 
of eosinophils and neutrophils changes as they migrate into 
the lung tissue  (32-34).  In addition, an increased number 
of cytoplasmic lipid bodies has been associated with the in 
vitro  formation of hypodense  neutrophils and  eosinophils 
(35, 36). Therefore, we hypothesized that cytoplasmic lipid 
bodies could be the cellular site of the TG pool of AA. If 
this were the case, neutrophils from ARDS patients would 
be expected to contain an increased number of lipid bodies 
as  compared with  blood neutrophils.  This hypothesis was 
addressed in the next set of experiments. Fig. 3  shows the 
microscopic appearance  of lipid bodies stained with  fluo- 
rescent  Nile  red  in  neutrophils  freshly  isolated from  the 
BAL fluid or from peripheral blood of a normal donor. Cy- 
toplasmic lipid bodies were significantly more numerous in 
BAL  neutrophils  from  ARDS  patients  than  they were  in 
normal peripheral blood cells (8  +  3 vs 2  +  1/cell, respec- 
tively). We postulated that a key mechanism leading to the 
increase in  total  cellular AA,  in  AA  associated with  TG, 
Table 3.  Fatty Acid Content of Neutral Lipids of Normal Blood Neutrophils and BAL Neutrophils 
Neutrophils  LA  OA  AA  Ratio LA/AA  Ratio OA/AA 
nmols / 106 cells 
Blood neutrophils  0.12  +  0.02  0.53  -  0.09  0.06 +  0.02  3.35  -4- 1.83  12.26  +  4.63 
BAL neutrophils  0.84  +  0.25  4.81  -  1.44  0.78 -+ 0.14  1.05  +  0.18  5.84 +  1.02 
Peripheral blood neutrophils and neutrophils from BAL of ARDS patients were isolated as described in Materials and Methods. The neutral lipids 
were isolated by normal-phase HPLC, and fatty acids were isolated by base hydrolysis. The mole quantities ofLA, OA, and AA were determined by 
NICI-GC/MS. The data are expressed as nmoles of fatty acid/106 cell and are the mean +  SE of three experiments. 
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BAL of a patient with ARDS (right). X20. 
and in the number of lipid bodies in the lung cells  may be 
the exposure to high concentrations of fatty acids. To begin 
to test  this hypothesis in ARDS patients,  the levels of un- 
saturated  fatty  acids  were  measured  in  the  cell-free  BAL 
fluids  by  GC/MS.  BAL fluids  from ARDS  patients  con- 
tained 0.08  +  0.03 nmol/ml  ofAA, a value almost three- 
fold higher than  that found in six BAL fluids from normal 
volunteers (0.03  +  0.01  nmol/ml). 
Influence  of  the  Extracellular  Concentration  of AA  on  the 
Amount  of AA  Esterifiecl  into  TG  in  Blood  Neutrophils  In 
Vitro.  The  data obtained in vivo in patients  with ARDS 
strengthened the hypothesis that inflammatory cells  migrat- 
ing in the lung tissue had an increased content of AA and a 
larger pool of AA in TG as well as an increased number of 
lipid bodies.  Furthermore,  these  data suggested that expo- 
sure of the cells to high concentrations of extracellular AA 
could  contribute  to  these  biochemical  and  morphological 
changes.  To further test this  hypothesis,  an in vitro model 
was developed to determine whether raising the intracellu- 
lar  levels  of AA would  result  in  the  accumulation  of AA 
into  TG.  In these  experiments,  we incubated  the  neutro- 
phils in culture  for 24 h  with  increasing concentrations of 
exogenous AA (10-100  p~M). Fig.  4  shows  that  exposure 
of neutrophils to exogenous AA induced a dose-dependent 
increase in the quantity of AA found in neutral lipids.  Pre- 
vious studies demonstrated that the bulk of AA in this neu- 
tral lipid fraction was in TG  (37, 38).  TG became the ma- 
jor  AA-containing  glycerolipid  in  neutrophils 
supplemented  with  50  or  100  txM  AA.  Unsupplemented 
levels of AA in TG increased by as much as 10-fold in sup- 
plemented  neutrophils.  The  only  phospholipid  class  that 
significantly increased its AA content was PC.  In contrast, 
the AA content of PE,  phosphatidylinositol  (PI),  or phos- 
phatidylserine  (PS)  was not changed by the  supplementa- 
tion procedure. 
To confirm that the presence of AA in the TG pool was 
associated  with  cytoplasmic lipid  bodies  and with  the  hy- 
podense  phenotype,  neutrophils  were  exposed in  vitro  to 
various  concentrations of exogenous AA, and the number 
of lipid bodies together with  the percentage  of hypodense 
cells  was measured (Table 4).  These data show that AA in- 
duces  a  significant  increase  in  the  number  of lipid  bodies 
per  cell.  Furthermore,  supplementation  with  AA also  in- 
creased the percentage of hypodense neutrophils in a dose- 
dependent fashion so that >50% ofneutrophils exposed to 
100 b~M AA for 24 h were hypodense. 
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Figure  4.  Distribution of AA in the glycerolipid classes of neutrophils 
isolated from the blood of normal donors and supplemented in vitro with 
increasing concentrations of AA for 24 h. At the end of the incubation, 
cells were harvested, and then lipids were extracted and separated by nor- 
mal-phase HPLC.  The  quantity of AA in  each  class  was measured by 
NICI-GC/MS.  The results are expressed as nanomoles of AA/106 cells 
and are the mean +  SE of four experiments. 
Table 4.  Effect  of  AA Supplement of Cellular AA Content, 
Number of Lipid Bodies, and Formation of Hypodense Cells 
Supplement  AA content  Lipid bodies  Hypodense cells 
nmoles  / l O  6 cells  No. ~cell  % 
None  1.17 +  0.21  3.1  -  0.6  23.5 +  3.9 
10 IxM AA  2.11 +  0.47  6.4 -4- 1.3  31.8 •  5.7 
50 IxM AA  3.87 +  1.12  12.9 •  3.4  46.3 -  8.5 
100 IxM AA  12.43  +  3.73  17.9 •  4.5  52.5 +  2.4 
Neutrophils from peripheral blood of healthy donors were isolated and 
incubated with various concentrations of AA. At the end of the incuba- 
tion,  the cells were harvested and lipids were extracted.  Total cellular 
AA was measured by NICI-GC/MS.  Lipid bodies were  stained with 
Nile red and counted under a fluorescent microscope. Hypodense cells 
were  determined after centrifugation over Ficoll-Paque  density gradi- 
ents  (density  1.077).  These  data are  the  mean  +  SE  of four  experi- 
ments. 
Discussion 
Results in this study support the hypothesis that migra- 
tion of inflammatory cells into the lung or other sites where 
there are large concentrations of AA induces a fundamental 
and  consistent  remodeling  of AA  pools,  leading  to  mor- 
phologic and densitometric changes in the cells.  This pos- 
tulate is supported by the following five lines of evidence. 
First,  cells  reaching  their  maturation  or  moving into  the 
lung  (mast cells,  macrophages, and lung neutrophils)  con- 
tain larger quantities of cellular AA than most inflammatory 
cells circulating in the blood (eosinophils, neutrophils,  and 
platelets). Second, resident lung cells contain a large amount 
of their AA esterified into  TG.  In fact, this pool contains 
the bulk of AA in all glycerolipids (including phospholip- 
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ids)  in the human lung mast cells.  Third, blood inflamma- 
tory cells like the neutrophils, which do not normally con- 
tain a significant TG pool, acquire large quantities of AA in 
TG as they migrate into the lung in vivo. Fourth,  the ac- 
quisition of AA into the TG pool is associated with an in- 
creased number of cytoplasmic lipid bodies and with a re- 
duction  in  cell  density,  as  determined  by  Ficoll-Paque 
density gradients. Fifth, the accumulation of AA in TG, an 
increase in the number of lipid bodies, and a reduction in 
cell density can all be seen simultaneously in vitro by expo- 
sure of the cells to high concentrations of AA. 
Over the  last 5  yr, several studies  have focused on  the 
cellular  and  functional  characterization  of inflammatory 
cells as they move into tissues.  For example, in asthma, the 
appearance of hypodense eosinophils in the lung has been 
correlated  to  disease  severity  (39).  However,  the  precise 
toxic role that these cells have in diseases such as asthma has 
not been clearly established (40).  It is known that lung in- 
flammatory  cells  have  a  different  capacity  to  synthesize 
oxygenase-derived metabolites  of AA  (eicosanoids)  when 
compared with  their respective blood counterparts  (9-11, 
40). The current finding that inflammatory cells that either 
reside in or migrate into the lung have fundamentally dif- 
ferent glycerolipid pools of AA raises  important questions 
as to the role of these pools in AA metabolism. 
One hypothesis is that AA-containing TG in lipid bodies 
are major sources of AA for eicosanoids.  This postulate is 
supported  by  recent  studies  by  A.  M.  Dvorak  and  col- 
leagues  that  have  demonstrated  that  lipid  bodies  contain 
prostaglandin  G/H  synthase,  the  key enzyme responsible 
for prostaglandins,  and thromboxane biosynthesis (41-43). 
However, it is not known whether there  is an enzyme(s) 
(TG lipase)  in these cellular organeUes that mobilizes AA in 
response to cell activation from the large reservoir of TG. 
This activity would be necessary to initiate eicosanoid bio- 
synthesis. 
An alternative hypothesis is that TG serves as an expand- 
able pool of AA to protect cells and tissues  from extremely 
high concentrations of AA.  For example, BAL fluids from 
the  ARDS  patients  in  our  study  contained  30  ng/ml  of 
unesterified AA.  It has been calculated that the amount of 
saline injected  into  the  bronchus  to  perform BAL would 
dilute the alveolar lining fluid ~50- to 100-fold (44). Thus, 
the  concentrations  of free AA to which  the lung neutro- 
phils  were  exposed may range from 5  to  10  jxM.  Tissue 
damage could be extensive if inflammatory cells used such a 
large  amount  of AA to  synthesize  proinflammatory eico- 
sanoids. Tissue cells may have the capacity to remove large 
quantities of unesterified AA from tissues  by using the TG 
pool. In the case ofAR.DS, neutrophils appear to be loaded 
with AA in TG and with cytoplasmic lipid bodies. In fact, 
they have an AA content in their TG pool that is increased 
'~30-fold,  with little  change  in  the  AA content  of phos- 
pholipids.  This  hypothesis  is  further  supported by our in 
vitro  studies,  which  demonstrate  a  direct  correlation  be- 
tween the exposure of neutrophils  to different concentra- 
tions of AA and the appearance of AA in TG as well as the 
number of lipid bodies. Finally,  a third hypothesis suggests that the  TG pool of 
AA represents  a biochemical marker for inflammatory cells 
exposed  to  prolonged  stimulation  (24).  In  this  case,  TG 
may act as  a  pool  to  recapture  AA released  intracellularly 
during  pathophysiological  conditions  in  which  a  massive 
activation ofphospholipase a 2 or other M-mobilizing en- 
zymes occurs. This hypothesis is supported by the observa- 
tion that AA content  in TG  increases  in rat hearts  during 
myocardial ischemia,  a condition generally associated with 
an  intense  AA mobilization  from the  phospholipid  pools 
(45, 46). 
The biochemical pathway responsible for the appearance 
of AA-containing TG has not been elucidated.  However, 
the current findings suggest that the size of TG may be rap- 
idly expanded in tissue ceils, since the content of fatty acids 
other than AA, such as LA and OA, also increased in TG of 
BAL  neutrophils  from  A1KDS  patients.  Previous  studies 
from this  and  other  laboratories  have  suggested  that  AA- 
containing  TG  can  be  rapidly  synthesized  in  neutrophils 
and HL-60 cells  by de novo glycerolipid biosynthesis  (37, 
47).  This pathway of formation of TG is supported by the 
observation that a key intermediate,  1,2-diarachidonoyl-sn- 
glycerol, can be  isolated when  neutrophils  are  exposed to 
high  concentrations  of  AA.  Neutrophils  supplemented 
with  A_A  also  produce  1,2-diarachidonoyl-sn-glycero-3- 
phosphocholine.  Both  1,2-diarachidonoyl-sn-glycerol and 
1,2-diarachidonoyl-sn-glycero-3-phosphocholine  are likely 
products of the  de novo glycerolipid biosynthesis and  not 
of the deacylation-reacylation pathway. 
In conclusion, this paper centers on the observation that 
inflammatory  cells  that  reside  in  or  move  into  the  lung 
have different glycerolipid pools of AA than inflammatory 
cells circulating in the blood. This remodeling of AA pools 
may  represent  a  crucial  event  that  alters  AA  metabolism 
during  inflammatory  diseases  of the  lung  such  as  AIKDS 
and asthma. 
This work was supported  in part by grants from NATO (Brussels, Belgium) (CP, G 910977), from the Con- 
siglio Nazionale delle 1Kicerche (R.ome, Italy), from the Associazione Italiana per la Ricerca Sul Cancro, and 
from the National  Institutes of Health  (Bethesda, MD) (AI 24985 and HE 50395). 
Address correspondence  to Dr.  Floyd H. Chilton,  Section on Pulmonary Medicine,  Bowman Gray School 
of Medicine,  Medical Center Boulevard, Winston-Salem  NC 27157-3923. 
Received for publication  31 March  t995 and in revised form  l June  1995. 
References 
1. Bochner, B.S., and L.M. Lichtenstein.  1991. Anaphylaxis.  N. 
Engl. J. Med. 324:1785-1790. 
2.  Chilton,  F.H., and L.M. Lichtenstein.  1990.  Lipid mediators 
of the allergic reaction. Chem. Immunol. 49:173-205. 
3.  Hartel,  B., R. Morwinski, D. Heydeck, and B. Papies.  1991. 
Arachidonic  acid  metabolism  in  cultured  adult  myocardial 
cells  under  short-time  hypoxic  conditions.  Mol.  Cell. Bio- 
chem. 106:67-73. 
4.  Coffey, M., M. Peters-Golden, J.  Fantone, and P.H.  Spore. 
1992. Membrane association of active 5-1ipoxygenase in rest- 
ing cells. Evidence for novel regulation of the enzyme in the 
rat alveolar macrophage.d. Biol. Chem. 267:570-576. 
5. Diez, E., F.H. Chilton, G. Stroup, R.J. Mayer, J.D. Winkler, 
and A.N. Fonteh. 1994. Fatty acid and phospholipid selectiv- 
it,/of different  phospholipase  A2 enzymes studied  by using a 
mammalian membrane as substrate.  Biochem.  J. 301:721-726. 
6.  Neagos, G.1K., A. Feyssa, and M. Peters-Golden.  1993. Phos- 
pholipase  A2 in alveolar  type II epithelial  cells: biochemical 
and immunologic characterization.  Am, J. Physiol. 264:L261- 
L268. 
7.  Red@,  S.T.,  and  H.R.  Herschman.  1994.  Ligand-induced 
prostaglandin  synthesis  requires  expression  of the  TIS10/ 
PGS-2 prostaglandin  synthase gene in routine fibroblasts and 
macrophages.J. Biol. Chem. 269:15473-15480. 
8.  Sedgwick, J.B.,  W.J.  Calhoun, R.F.  Vrtis,  M.E. Bates,  P.K. 
McAllister,  and W.W.  Busse.  1992.  Comparison of airway 
and blood eosinophil function after in vivo antigen challenge. 
J. Immunol.  149:3710-3718. 
9.  Kroegel,  C.,  M.C.  Liu,  W.C.  Hubbard,  L.M.  Lichtenstem, 
and B.S. Bochner. 1994. Blood and bronchoalveolar eosino- 
phils  in  allergic  subjects  after  segmental  antigen  challenge: 
surface  phenotype,  density  heterogeneity,  and  prostanoid 
production.d. Allergy Clin. lmmunol.  93:725-734. 
10. Coffey, M.J., M. Gyetko, and M. Peters-Golden.  1993. 1,25- 
Dihydroxyvitamin D3  upregulates  5-1ipoxygenase  metabo- 
lism  and  5-1ipoxygenase  activating  protein  in  peripheral 
blood  monocytes as  they  differentiate  into  mature  macro- 
phages..].  Lipid Mediators. 6:43-51. 
11. Coffey, MJ.,  S.E.  Wilcoxen,  and M.  Peters-Golden.  1994. 
Increases in 5-1ipoxygenase activating protein expression  ac- 
count for enhanced capacity  for 5-1ipoxygenase  metabolism 
that accompanies differentiation  of peripheral  blood mono- 
cytes into alveolar macrophages.  Am. J. Respir. Cell Mol. Biol. 
1I:153-158. 
12. Busse,  W.W., J.B.  Sedgwick,  N.N. Jarjour,  and W.J.  Cal- 
houn.  1994. Eosinophils  and basophils  in allergic airway in- 
flammation.J. Allergy Clin.  bnmunol.  94:1250-1254. 
13. Calhoun, W.J., N.N. Jarjour, G.J. Gleich,  C.A. Stevens,  and 
W.W. Busse.  1993.  Increased  airway inflammation with seg- 
mental versus aerosol antigen challenge. Am. Rev. Respir. Dis. 
147:1465-1472. 
14. Georas, S.N., M.C. Liu, W. Newman, L.D. Beall, B.A. Stea- 
ley, and B.S. Bochner.  1992. Altered adhesion  molecule ex- 
pression  and  endothelial  cell  activation  accompany the  re- 
cruitment of human granulocytes to the lung after segmental 
antigen challenge.  Am.J.  Respir. Cell Mol.  Biol. 7:261-269. 
1188  Remodeling of  Arachidonic Acid in the Lung 15. Weller,  P.F.  1992.  Cytokine regulation  of eosinophil func- 
tion.  Clin.  Immunol.  Immunopathol.  62:$55-$59. 
16. Ohnishi, T., H. Kita, D. Weiler, S. Sur, J.B. Sedgwick, W.J. 
Calhoun, W.W. Busse, J.S.  Abrams,  and G.J.  Gleich.  1993. 
IL-5 is the predominant eosinophil-active cytokine in the an- 
tigen-induced pulmonary late-phase reaction. Am. Rev. Respir. 
Dis.  147:901-907. 
17. Owen, W.J., J. Petersen,  and K.F. Austen.  1991. Eosinophils 
altered  phenotypically and primed by culture with granulo- 
cyte/macrophage  colony-stimulating factor and  3T3  fibro- 
blasts generate leukotriene C4 in response  to FMLP. J.  Clin. 
Invest. 87:1958-1963. 
18. Murakami,  M., R. Matsumoto, Y. Urade, K.F.  Austen, and 
J.P. Arm. 1995. c-kit ligand mediates  increased  expression  of 
cytosolic phospholipase  A2, prostaglandin  endoperoxide syn- 
thase-1,  and hematopoietic prostaglandin  D2 synthase and in- 
creased  IgE-dependent prostaglandin  D2  generation  in im- 
mature mouse mast cells..].  Biol.  Chem. 270:3239-3246. 
19. Brock, T.G., R., Paine III, and M. Peters-Golden.  1994. Lo- 
calization  of 5-1ipoxygenase  to  the  nucleus of unstimulated 
rat basophilic leukemia  cells..]. Biol. Chem.  269:22059-22060. 
20.  Peters-Golden, M., and R.W. McNish. 1993. Redistribution 
of 5-1ipoxygenase  and cytosolic phospholipase  A2 to the nu- 
clear fraction upon macrophage activation.  Biochem.  Biophys. 
Res. Commun.  196:147-153. 
21. Woods, J.W., J.F. Evans, D. Ethier, S. Scott, P.J. Vickers,  L. 
Hearn, J.A.  Heibein,  S.  Charleson,  and I.I. Singer.  1993. 
5-1ipoxygenase  and 5-1ipoxygenase-activating  protein are lo- 
calized  in  the  nuclear  envelope  of activated  human  leuko- 
cytes.J. Exp. Med. 178:1935-1946. 
22.  Fonteh, A.N., and F.H.  Chilton.  1993. Mobilization of dif- 
ferent arachidonate pools and their roles in the generation of 
leukotrienes  and free  arachidonic acid during immunologic 
activation of mast cells. J. ImmunoI.  150:563-570. 
23.  Fonteh,  A.N.,  D.A.  Bass, L.A.  Marshall,  M.  Seeds,  J.M. 
Samet,  and  F.H.  Chilton.  1994.  Evidence  that  secretory 
phospholipase A2 plays a role in arachidonic acid release and 
eicosanoid biosynthesis  by mast cells. J.  Immunol.  152:5438- 
5446. 
24. Triggiani,  M., A. Oriente, and G. Marone. 1994. Differential 
roles  for triglyceride  and phospholipid pools of arachidonic 
acid  in  human  lung  macrophages, d.  Immunol.  152:1394- 
1403. 
25.  Chilton,  F.H.,  M. Patel,  A.N. Fonteh, W.C.  Hubbard, and 
M. Triggiani.  1993. Dietary n-3 fatty acid effects on neutro- 
phil lipid composition and mediator production. Influence of 
duration and dosage. J.  Clin.  Invest. 9"1 :  115-122. 
26. Hansel,  T.T., V.I. De, T. Iff, S. Rihs, M. Wandzilak, S. Betz, 
K. Blaser, and C. Walker.  1991. An improved immunomag- 
netic  procedure  for the  isolation  of highly purified  human 
blood eosinophils.J.  Immunol.  Methods.  145:105-111. 
27.  Golino, P.,  G. Ambrosio, M. Ragni,  I. Pascucci,  M. Triggi- 
ani,  A.  Oriente, J.  McNatt,  L.M. Buja,  M.  Condorelli, and 
M. Chiariello.  1993. Short-term and long-term role of plate- 
let activating factor as a mediator of in vivo platelet  aggrega- 
tion.  Circulation. 88:1205-1214. 
28. Triggiani,  M., R.P.  Schleimer,  J.A. Warner, and F.H.  Chil- 
ton.  1991.  Differential  synthesis  of 1-acyl-2-acetyl-sn-glyc- 
ero-3-phosphocholine  and platelet-activating  factor by hu- 
man inflammatory cells._/. Immunol.  147:660-666. 
29. Weller, P.F.,  S.W. Ryeom, S.T. Picard,  S.J. Ackerrnan,  and 
A.M. Dvorak. 1991. Cytoplasmic lipid bodies  of neutrophils: 
formation induced by cis-unsaturated  fatty  acids and medi- 
ated by protein kinase c.J.  Cell Biol.  113:137-146. 
30. Bligh,  E.G.,  and W.J.  Dyer.  1959.  A rapid  method of total 
lipid extraction and purification.  Can. J. Biochem. Physiol. 37: 
911-923. 
3l. Campbell, G.S.,  and J.B. Cone.  1991. Adult respiratory  dis- 
tress syndrome. Am..].  Surg. 161:239-242. 
32.  ChoUet-Martin, S., P. Montravers, C. Gibert,  C. Elbim, J.M. 
Desmonts, J.Y.  Fagon, and M.A.  Gougerot-Pocidalo. 1992. 
Subpopulation of hyperresponsive polymorphonuclear neu- 
trophils  in patients  with adult respiratory  distress syndrome. 
Role ofcytokine production. Am. Rev. Respir. Dis.  146:990-- 
996. 
33. Lin,  C.C.,  and  C.Y.  Lin.  1992.  Enhanced  chemilumines- 
cence with decreased  antibody-dependent cellular cytotoxic- 
ity of human alveolar neutrophil in patients  with adult respi- 
ratory distress syndrome. Respiration.  59:265-271. 
34. Rimmer,  S.J., C.L.  Akerman,  T.C.  Hunt,  M.K.  Church, 
S.T.  Holgate, andJ.K. Shute.  1992. Density profile  ofbron- 
choalveolar lavage eosinophils  in the guinea pig model of al- 
lergen-induced  late-phase  allergic  responses.  Am. J.  Respir. 
Cell Mol.  Biol. 6:340-348. 
35. Weller,  P.F.,  R.A. Monahan-Earley, H.F. Dvorak, and A.M. 
Dvorak.  1991.  Cytoplasmic lipid  bodies  of human  eosino- 
phils. Subcellular  isolation  and analysis ofarachidonate incor- 
poration. Am.J,  Pathol.  138:141-148. 
36.  Caulfield, J.P., A. Hein, M.E. Rothenberg, W.F. Owen, R.J. 
Soberman, R.L. Stevens, and K.F. Austen.  1990. A morpho- 
metric study of normodense and hypodense human eosino- 
phils that are derived in vivo and in vitro. Am. J. Pathol.  137: 
27-34. 
37. Chilton, F.H., and R.C.  Murphy. 1987.  Stimulated  produc- 
tion  and  natural  occurrence  of 1,2-diarachidonoylglycero- 
phosphocholine in human neutrophils.  Biochem. Biophys.  Res. 
Commun.  145:1126-1133. 
38. Brezinski,  M.E., and C.N. Serhan.  1990. Selective incorpora- 
tion  of 15S-hydroxyeicosatetraenoic acid  in  phosphatidyli- 
nositol  of human  neutrophils:  agonist-induced  deacylation 
and transformation of stored hydroxyeicosanoids. Proc. Natl. 
Acad.  Sci. USA. 87:6248-6252. 
39. Kuo, H.P., T.R. Yu, and C.T. Yu.  1994.  Hypodense eosi- 
nophil  number  relates  to  clinical  severity,  airway hyperre- 
sponsiveness  and response  to inhaled corticosteroids  in asth- 
matic subjects. Eur.  Respir.J.  7:1452-1459. 
40.  Chanez, P., J. Bousquet, I. Couret, L. Cornillac,  G. Barneon, 
P. Vic, F.B. Michel, and P. Godard. 1991. Increased numbers 
ofhypodense alveolar macrophages in patients with bronchial 
asthma. Am. Rev. Respir. Dis.  144:923-930. 
41. Dvorak, A.M., E.S. Morgan, D.M.  Tzizik, and P.F.  Weller. 
1994. Prostaglandin  endoperoxide synthase (cyclooxygenase): 
ultrastructural  localization  to nonmembrane-bound cytoplas- 
naic lipid  bodies in  human  eosinophils  and 3T3  fibroblasts. 
Int.  Arch. Allergy Immunol.  105:245-250. 
42. Dvorak, A.M., P.F.  Weller,  V.S. Harvey, E.S.  Morgan, and 
H.F. Dvorak. 1993. Ultrastructural  localization  ofprostaglan- 
din endoperoxide synthase (cyclooxygenase)  to isolated, puri- 
fied fractions of guinea pig peritoneal macrophage and line 10 
hepatocarcinoma cell lipid bodies.  Int.  Arch.  Allergy  Immunol. 
101:136-142. 
43. Weller,  P.F.,  and  A.M.  Dvorak.  Lipid  bodies:  intracellular 
sites for eicosanoid formation. 1994. J. Allergy  Clin.  Immunol. 
94:1151-1156. 
44. Driver,  A.G.,  C.A.  Kukoly, S. Ali,  and S.J. Mustafa.  1993. 
Adenosine  in  bronchoalveolar lavage  fluid  in  asthma.  Am. 
1189  Triggiani et al. Rev. Respir.  Dis.  148:91-97. 
45. Burton,  K,P., L.M. Buja, A. Sen, J.T.  Willerson, and K.R. 
Chien.  1986.  Accumulation of arachidonate in triacylglycer- 
ols and unesterified fatty acids during ischemia and reflow in 
the isolated rat heart. Correlation with the loss of contractile 
function and the  development of calcium overload. Am. J. 
Pathol.  124:238-245. 
46. de Groot, M., W.A. Coumans, P.H. Willemsen, and G.J. van 
der Vusse.  1993.  Substrate-induced changes in the lipid con- 
tent of ischemic and reperfused myocardium. Its relation to 
hemodynamic recovery. Circ. Res. 72:176-186. 
47. Blank, M.L., Z.L. Smith, and F. Snyder. 1993. Arachidonate- 
containing triacylglycerols:  biosynthesis and a lipolytic mech- 
anism for the release and transfer ofarachidonate to phospho- 
lipids in HL-60 cells. Biochim.  Biophys.  Acta.  1170:275-282. 
1190  Remodeling of Arachidonic Acid in the Lung 